Please Wait...

Luc Bracoud

Translation skills

Main profile

Luc Bracoud, MSc
Director, Neuroscience

Luc Bracoud graduated from Ecole Centrale Lyon in 2001. He joined Theralys in 2002, which was later acquired by BioClinica (formerly known as Bio-Imaging Technologies) as a software developer and medical image processing engineer. He also served as a project manager, and has been involved in various large multi-center clinical trials mainly in Stroke, MS and AD, as well as Gaucher Disease. His main image processing activities are related to spatial registration, segmentation, atrophy quantification, perfusion imaging, diffusion and diffusion tensor imaging.

Authored Publications

Serge Gauthier, MD, Howard H Feldman, MD, Lon S Schneider, MD, Gordon K Wilcock, DM, Giovanni B Frisoni, MD, Jiri H Hardlund, MD, Hans J Moebius, MD, Peter Bentham, MBChB, Karin A Kook, PhD, Damon J Wischik, PhD, Bjoern O Schelter, Charles S Davis, PhD, Roger T Staff, PhD, Luc Bracoud, MSc, Kohkan Shamsi, MD, John M D Storey, Charles R Harrington, PhD, Claude M Wischik, MBBS.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. 15 November 2016. DOI: http://dx.doi.org/10.1016/S0140-6736(16)31275-2.

Coric V, Salloway S, H. van Dyck C, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM. Targetting Prodromal Alzheimer Disease with Avagacestat A Randomized Clinical Trial.  JAMA Neurol 2015, Sept 28. [Epub ahead of print]

Sibon I, Tourdias T, Felix S, Asselineau J, Bracoud L, Vivot A, Rouanet F, Renou P, Orgogozo JM, Dousset V. Magnetisation transfer parameters and stroke outcome. J Clin Neurosci. 2015 Jun;22(6):1012-7.

Kufner A, Wouters A, Bracoud L, Laage R, Schneider A, Schäbitz W, Hermier M, Thijs V, Fiebach JB, on behalf of the AXIS2 investigators.  Infarct Volume-Based Subgroup Selection in Acute Ischemic Stroke Trials. Stroke, May 2015.

Opherk C, Gonik M, Duering M, Malik R, Jouvent E, Hervé D, Adib-Samii P, Bevan S, Pianese L, Silvestri S, Dotti MT, De Stefano N, Liem M, Boon EM, Pescini F, Pachai C, Bracoud L, Müller-Myhsok B, Meitinger T, Rost N, Pantoni L, Oberstein SL, Federico A, Ragno M, Markus HS, Tournier-Lasserve E, Rosand J, Chabriat H, Dichgans M. Genome-Wide Genotyping Demonstrates a Polygenic Risk Score Associated With White Matter Hyperintensity Volume in CADASIL. Stroke. 2014 Feb 27. [Epub ahead of print]

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Think a #CTMS implementation takes too much time and too many resources? It doesn’t have to. Learn how a configurab… https://t.co/yowxvVTyP3
Bioclinica (2 days ago)
We think you should have access to the full suite of #ClinicalDataManagement services to ensure high-quality, relia… https://t.co/jVuliQwFo3
Bioclinica (2 weeks ago)
A mid-study change to a new #IRT vendor can be required for a number of reasons and can introduce a certain amount… https://t.co/sU7akWjdCD
Bioclinica (2 weeks ago)
A clinical trial rescue or transition presents a unique set of challenges for study teams. Join us on July 21 for a… https://t.co/rlYiFYpR6G
Bioclinica (3 weeks ago)
Rapid #CTMS implementation shouldn’t mean sacrificing features and functionality. With a modular approach, a full-f… https://t.co/gwqFtB8lhe
Bioclinica (4 weeks ago)
How prepared are you for a #clinicaltrial transition? With proper planning, the impact to sites and patients can be… https://t.co/vOqwC5vzzd
Bioclinica (5 weeks ago)